Simvastatin can re-sensitize sorafenib-resistant HCC cells by inhibiting the hypoxia-inducible 280 factor-1α/PPAR-γ/PKM2 axis and suppressing PKM2-mediated glycolysis, as demonstrated in vitro [37]. The gene discussed is PPARG; the disease is hepatocellular carcinoma.